Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab combined with IMRT and concurrent cisplatin for locally advanced nasopharyngeal carcinoma
ChiCTR-TNC-08000116Phase 4Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2008
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cetuximab and cisplatin in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Primary endpoint: 3-month loco-regional control rate. Started Apr 2008; status: recruiting.
02
Drugs
cetuximabcisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR-TNC-08000116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TNC-08000116.